Exactly they're mitigating risk as bio/pharma do.
They're paying a small amount upfront and funding the next phase of clinical trials - it's very different, if the drug the flops they can walk out with a few scratches but relatively untouched -if they put it all upfront they take that risk onboard themselves.
Ann: Change of Director's Interest Notice, page-78
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.70 |
Change
-0.310(2.38%) |
Mkt cap ! $1.623B | |||
| Open | High | Low | Value | Volume |
| $12.80 | $12.90 | $12.69 | $5.154M | 403.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 4631 | $12.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.76 | 1060 | 1 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |